Reviewer's report
Title:Remifentanil ameliorates intestinal ischemia-reperfusion injury
Version: 1Date:28 November 2012
Reviewer: Carlos Medina Martin
Reviewer's report:
Re: 'Remifentanil ameliorates intestinal ischemia-reperfusion injury '
Steven SC Cho, Ina Rudloff, Philip J Berger, Marcel F Nold, Michael G Irwin, Wei
Cheng and Claudia A Nold-Petry
1. Is the question posed by the authors well defined? Yes
2. Are the methods appropriate and well described? Yes
3. Are the data sound? Yes
4. Does the manuscript adhere to the relevant standards for reporting and data
deposition? Yes
5. Are the discussion and conclusions well balanced and adequately supported
by the data? Yes
6. Are limitations of the work clearly stated? No
7. Do the authors clearly acknowledge any work upon which they are building,
both published and unpublished? Yes
8. Do the title and abstract accurately convey what has been found? Yes
9. Is the writing acceptable? Yes
Please make your review as constructive and detailed as possible in your
comments so that authors have the opportunity to overcome any serious
deficiencies that you find and please also divide your comments into the following
categories:
- Major Compulsory Revisions
Dear Editor,
In this study, authors show that Remifentanil is useful in the management of
intestinal ischaemia/reperfusion in mice by assessing histological damage, MDA
and IL-6. This is a commendable aim as there is little known on the
treatment/preconditioning of this disease with severe consequences. Although
the subject matter of the paper is of interest, the main concern is that some of the
data sets seem rather preliminary and mechanistic studies are completely
absent. Overall, this study does not provide a solid insight into the action of
Remifentanil on intestinal ischemia/reperfusion. More studies should be carried
out in order to elucidate how remifentanil works in this condition, for instance any
affect of the drug on MAPK phosphorylation.
Reviewer's report
Title:Remifentanil ameliorates intestinal ischemia-reperfusion injury
Version: 1Date:28 November 2012
Reviewer: Carlos Medina Martin
Reviewer's report:
Re: 'Remifentanil ameliorates intestinal ischemia-reperfusion injury '
Steven SC Cho, Ina Rudloff, Philip J Berger, Marcel F Nold, Michael G Irwin, Wei
Cheng and Claudia A Nold-Petry
1. Is the question posed by the authors well defined? Yes
2. Are the methods appropriate and well described? Yes
3. Are the data sound? Yes
4. Does the manuscript adhere to the relevant standards for reporting and data
deposition? Yes
5. Are the discussion and conclusions well balanced and adequately supported
by the data? Yes
6. Are limitations of the work clearly stated? No
7. Do the authors clearly acknowledge any work upon which they are building,
both published and unpublished? Yes
8. Do the title and abstract accurately convey what has been found? Yes
9. Is the writing acceptable? Yes
Please make your review as constructive and detailed as possible in your
comments so that authors have the opportunity to overcome any serious
deficiencies that you find and please also divide your comments into the following
categories:
- Major Compulsory Revisions
Dear Editor,
In this study, authors show that Remifentanil is useful in the management of
intestinal ischaemia/reperfusion in mice by assessing histological damage, MDA
and IL-6. This is a commendable aim as there is little known on the
treatment/preconditioning of this disease with severe consequences. Although
the subject matter of the paper is of interest, the main concern is that some of the
data sets seem rather preliminary and mechanistic studies are completely
absent. Overall, this study does not provide a solid insight into the action of
Remifentanil on intestinal ischemia/reperfusion. More studies should be carried
out in order to elucidate how remifentanil works in this condition, for instance any
affect of the drug on MAPK phosphorylation.
Please review this paper.
user
Reviewer's report
Title:Remifentanil ameliorates intestinal ischemia-reperfusion injury
Version: 1Date:28 November 2012
Reviewer: Carlos Medina Martin
Reviewer's report:
Re: 'Remifentanil ameliorates intestinal ischemia-reperfusion injury '
Steven SC Cho, Ina Rudloff, Philip J Berger, Marcel F Nold, Michael G Irwin, Wei
Cheng and Claudia A Nold-Petry
1. Is the question posed by the authors well defined? Yes
2. Are the methods appropriate and well described? Yes
3. Are the data sound? Yes
4. Does the manuscript adhere to the relevant standards for reporting and data
deposition? Yes
5. Are the discussion and conclusions well balanced and adequately supported
by the data? Yes
6. Are limitations of the work clearly stated? No
7. Do the authors clearly acknowledge any work upon which they are building,
both published and unpublished? Yes
8. Do the title and abstract accurately convey what has been found? Yes
9. Is the writing acceptable? Yes
Please make your review as constructive and detailed as possible in your
comments so that authors have the opportunity to overcome any serious
deficiencies that you find and please also divide your comments into the following
categories:
- Major Compulsory Revisions
Dear Editor,
In this study, authors show that Remifentanil is useful in the management of
intestinal ischaemia/reperfusion in mice by assessing histological damage, MDA
and IL-6. This is a commendable aim as there is little known on the
treatment/preconditioning of this disease with severe consequences. Although
the subject matter of the paper is of interest, the main concern is that some of the
data sets seem rather preliminary and mechanistic studies are completely
absent. Overall, this study does not provide a solid insight into the action of
Remifentanil on intestinal ischemia/reperfusion. More studies should be carried
out in order to elucidate how remifentanil works in this condition, for instance any
affect of the drug on MAPK phosphorylation.
assistant